Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics has appointed Thomas Christely as the company's new chief executive officer (CEO).
Subscribe to our email newsletter
Christely has collaborated with AstraZeneca, Pfizer, Dainippon Sumitomo, multiple financing transactions as well as M&A, divestments and strategic restructurings.
In 2001 he served Atugen as chief financial officer and became chief operating officer in 2002 before being appointed its chief executive officer in 2006.
Thomas served as a Senior VP and CFO at a Swiss pharmaceutical company – OXO Chemie and founded its subsidiary in San Francisco.
From 1992 to 1995 he served as a managing partner of the investment firm Loschen & Partner, Hamburg/Moscow and from 1989 to 1992 he also worked in mergers & acquisitions at Enskilda Corporate Finance, London.
A part from the Silence’ CEO, he is also a non-executive chairman of the Supervisory Board of Muller-Spreer.
Silence Therapeutics chairman Jerry Randall said they are confident that Thomas has the vision, expertise and experience necessary to move the company toward the achievement of its corporate and clinical objectives.
Silence TherapeuticCEO Thomas Christely said with his long term relationships already established with their partners over many years, he look forward to achieve further commercial success for clinical and pre-clinical assets.